Liver function tests, arterial blood gases (ABGs), chlamydia, strep A, HbA1c, and N-terminal pro–B-type natriuretic peptide (NT-proBNP) tests were available to <5% of clinicians. This evidence concerns the gene NPPB and chlamydia trachomatis infectious disease.